Kenvue Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KVUE research report →
Range $19 – $20
Price Chart
About the company
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health.
- CEO
- Kirk L. Perry
- IPO
- 2023
- Employees
- 21,890
- HQ
- Summit, NJ, US
AI snapshot
Six angles, distilled from the data.
KVUE remains in a constructive multi-month uptrend, trading above both the 50-day and 200-day moving averages. The stock is still near its 52-week high band, so the regime favors consolidation after a strong recovery rather than a deep-value setup.
Street sentiment is cautious-to-neutral: consensus is Hold with a 19.5 target, only modestly below the last close. Recent changes have been mostly reiterations and target resets, with one downgrade to Hold from Buy, which points to limited conviction for a sharp rerating.
Kenvue has beaten EPS in 6 of the last 8 quarters, including a 3.6% beat in the latest report. Next-year EPS is modeled at 1.2386 versus 0.88 TTM, so shareholders should watch whether margin discipline and steady consumer demand keep that path intact.
Recent insider activity leans heavily negative, but most of the volume is tied to automatic return-of-shares activity rather than open-market conviction. The only clear signal is net selling, led by repeated transactions from senior officers, with no notable insider buying to offset it.
Profitability is solid for a consumer staples name, with a 58.5% gross margin, 19.2% operating margin, and 10.9% net margin. Growth is steady rather than fast, with revenue up 3.2% year over year and earnings up 6.0%, while free cash flow reached $2.672 billion in 2025.
KVUE’s appeal is defensive scale and brand strength, but its growth profile is slower than higher-growth consumer names. At 16.36x earnings, it screens near the middle of the consumer staples pack rather than as a deep discount or premium multiple.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $37.09B
- P/E
- 21.94
- Fwd P/E
- 16.48
- PEG
- 1.27
- P/S
- 2.39
- P/B
- 3.65
- EV/EBITDA
- 13.61
- Div Yield
- 5.40%
- Gross Margin
- 58.30%
- Op Margin
- 17.43%
- Net Margin
- 10.88%
- ROE
- 16.06%
- ROIC
- 9.18%
Latest fiscal year · YoY change
- Revenue
- $15.12B-2.1%
- Gross Profit
- $8.79B-1.9%
- Op Income
- $2.41B
- Net Income
- $1.47B+42.7%
- EPS
- $0.77+42.6%
- OCF Growth
- +24.2%
- FCF Growth
- +29.0%
- 52W High
- $20.13
- 52W Low
- $15.94
- 50D MA
- $18.40
- 200D MA
- $18.22
- Beta
- 0.45
- RSI (14)
- 60
- Avg Volume
- 22.41M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kenvue posted a weak second quarter and cut 2025 guidance, while management signaled an aggressive turnaround, tighter focus, and an active strategic review of alternatives.· August 7, 2025
- Organic sales fell 4.2%; adjusted operating margin was 22.7%, adjusted EPS was $0.29 versus $0.32 a year ago, and adjusted gross margin was 60.9%.
- Global consumption outpaced organic sales across all segments, but management said execution, inventory timing, and soft seasonal demand weighed on the quarter.
- The Board is pursuing a comprehensive review of strategic alternatives, including possible portfolio optimization, while the company also pushes immediate operating changes.
- Management highlighted self-induced complexity: 115 brands, but 41 drive over 3/4 of sales; the long tail of SKUs contributes about 1% of sales.
- Full-year 2025 guidance was cut to low-single-digit organic sales decline, adjusted operating margin down versus last year, and adjusted EPS of $1.00 to $1.05.
- Tariffs are now expected to carry about a $150 million annualized gross impact, though below that in 2025 due to timing.
Second-quarter organic sales declined 4.2%. Adjusted gross margin contracted 70 basis points to 60.9%, adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS was $0.29 versus $0.32 a year ago. Adjusted net income was $560 million, and below-the-line items were unfavorable year over year, with net interest expense up about $2 million to $94 million and the adjusted tax rate at 26.9% versus 25.7%. For 2025, Kenvue now expects organic sales down low single digits, about neutral currency impact, adjusted operating margin to contract versus last year, tariff impact of about $150 million annualized gross and below that in 2025, and adjusted diluted EPS of $1.00 to $1.05 including a low-single-digit currency drag.
Kirk Perry framed the quarter as below expectations and said the company must move with urgency, simplify the portfolio, and sharpen execution. He emphasized consumer-centric brand building, better e-commerce execution, fewer and bigger innovation bets, and a more choiceful allocation of resources to the biggest brands, markets, and initiatives. His tone was urgent but confident, repeatedly saying the issues are fixable and that the team has turned around similar businesses before.
Amit Banati said the company has healthy gross margins but sees room to expand margins over time through supply chain productivity, procurement, network optimization, planning, and digitization. He also pointed to SG&A above peer benchmarks because of separation-related costs, plus opportunities to improve working capital and cash conversion. On the quarter, he cited the 4.2% organic sales decline, 60.9% gross margin, 22.7% adjusted operating margin, and $0.29 adjusted EPS, and said Q2 weakness came from softer categories, seasonal and inventory issues, U.S. pricing actions, and FX.
Analysts focused on the timing and scope of the turnaround, especially how much of the complexity could be reduced quickly versus through strategic portfolio changes. Management said the Board review is broad and ongoing, but it is too early to specify restructuring actions or cash costs; the near-term focus is on removing obvious SKU complexity, improving e-commerce, and concentrating on the biggest brands and markets. Questions also probed the outlook for the back half, and Amit said July trends still look similar to Q2, with consumption ahead of organic sales but seasons remaining weak, while Q4 should benefit from easier comparisons to last year’s trade accruals and China weakness.
Management pointed to clear pockets of strength: Tylenol has 12 consecutive quarters of U.S. share improvement, Nicorette has 7 consecutive quarters of share gains, and Neutrogena Face and OGX showed sequential or positive consumption improvement. They also said EMEA and Latin America were encouraging, global consumption in Skin Health and Beauty stabilized for the first time in more than a year, and the back half includes the most robust innovation pipeline in years. The Board’s strategic review could unlock portfolio or structural value if it leads to sharper focus.
The quarter showed a large gap between consumption and reported sales, and management said execution and share are not where they need to be. Category softness, weak allergy and sun seasons, retailer inventory swings, China timing issues, and price investments all pressured results, while July trends still looked similar to Q2. Management also acknowledged complexity, underdeveloped e-commerce, tougher conditions in North America and APAC, and margin pressure from tariffs, inflation, and strategic reinvestment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 1.92B
- Float Shares
- 1.92B
of shares held by institutions
1,044 13F filers
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KVUE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Jul 17, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 16, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Mar 13, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 17, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 10, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jan 9, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Oct 1, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 12, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 234.95M | ▲ 1.60M |
| Fmr LLC | 170.12M | ▲ 13.07M |
| Blackrock, Inc. | 150.65M | ▼ 180.67K |
| Vanguard Capital Management LLC | 125.44M | ▲ 122.27K |
| State Street Corp | 118.14M | ▼ 3.48M |
| Vanguard Portfolio Management LLC | 92.48M | ▼ 823.34K |
| Pentwater Capital Management LP | 65.44M | ▲ 14.31M |
| Geode Capital Management, LLC | 52.91M | ▲ 892.47K |
| Norges Bank | 46.16M | ▲ 46.16M |
| Massachusetts Financial Services Co | 42.42M | ▼ 2.29M |
| Hbk Investments L P | 38.29M | ▲ 10.29M |
| Millennium Management LLC | 34.63M | ▼ 2.31M |
Held by 454 ETFs
Biggest fund positions in KVUE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Wondrasch Michael | sell | 45,453 |
| Nov 2, 26 | Wondrasch Michael | sell | 215,876 |
| Nov 2, 26 | Tillett Caroline | sell | 77,709 |
| Nov 2, 26 | Tillett Caroline | sell | 111,009 |
| Nov 2, 26 | Tillett Caroline | sell | 113,957 |
| Nov 2, 26 | Tillett Caroline | sell | 39,705 |
| Nov 2, 26 | Tillett Caroline | sell | 74,422 |
| Nov 2, 26 | Tillett Caroline | sell | 73,348 |
| Nov 2, 26 | Tillett Caroline | sell | 75,541 |
| Nov 2, 26 | Tillett Caroline | sell | 81,837 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KVUE coverage
Recent articles, reports, and earnings notes.

Kenvue (KVUE): Improving Momentum, But Still a Hold
Kenvue is showing better sales, margin, and EPS momentum, but the stock still looks fairly valued rather than compellingly cheap. Its defensive brands and cash generation support the case, while leverage and execution risk keep the rating at Hold.

Kenvue Inc. (KVUE) slips on mixed earnings, deep dive
Kenvue Inc. (KVUE) slipped after a narrow EPS miss offset a revenue beat, but the deeper story is more nuanced. Self Care drove growth, Skin Health lagged, margins improved, and free cash flow strengthened, even as the company withheld guidance amid its Kimberly-Clark transaction.

Kenvue Inc. (KVUE) slips as earnings misses weigh on shares
Kenvue Inc. (KVUE) slips 0.6% after reporting earnings misses, pressuring the stock as investors react to weaker-than-expected results.
Want a deeper read on KVUE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Is Kimberly-Clark Stock a Buy Now That the Kenvue Acquisition Is Finalized?
fool.com · Nov 20
Kimberly-Clark: 2027 Recovery And Kenvue Synergies Make It A Buy
seekingalpha.com · Nov 12
The Dividend Portfolio That Covers Your Required Minimum Distribution Without Selling a Share: KMB, BIZD, and SPHD
247wallst.com · Nov 3
Can Kimberly-Clark's Kenvue Acquisition Unlock Long-Term Growth?
zacks.com · Nov 3
Kimberly-Clark Corporation Announces Expiration and Final Results of Exchange Offers for Kenvue Notes
prnewswire.com · Nov 3
Kimberly-Clark Acquires Kenvue. Here's What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.
fool.com · Nov 3
Kenvue Is Leaving the S&P 500: Here's What It Means for Investors
247wallst.com · Nov 2
Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader
prnewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice